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Abstract
Introduction: Few tools predict survival from pancreatic cancer (PAC). The McGill Brisbane Symptom
Score (MBSS) based on symptoms at presentation (weight loss, pain, jaundice and smoking) was recently
validated. The present study compares the ability of four strategies to predict 9-month survival: MBSS,
carbohydrate antigen 19-9 (CA 19-9) alone, CA19-9-to-bilirubin ratio and a combination of MBSS and the
CA19-9-to-bilirubin ratio.
Methodology: A retrospective review of 133 patients diagnosed with PAC between 2005 and 2011 was
performed. Survival was determined from the Quebec civil registry. Blood CA 19-9 and bilirubin values
were collected (n = 52) at the time of diagnosis. Receiver-operating characteristic (ROC) curves were used
to determine a cutoff for optimal test characteristics of CA 19-9 and CA19-9-to-total bilirubin ratio in
predicting survival at 9 months. Predictive characteristics were then calculated for the four strategies.
Results: Of the four strategies, the one with the greatest negative predictive value was the MBSS:
negative predictive value (NPV) was 90.2% (76.9–97.3%) and the positive likelihood ratio (LR) was the
greatest. The ability of CA 19-9 levels alone, at baseline, to predict survival was low. For the CA19-9-to-
bilirubin ratio, the test characteristics improved but remained non-significant. The best performing
strategy according to likelihood ratios was the combined MBSS and CA19-9 to the bilirubin ratio.
Conclusion: CA19-9 levels and the CA19-9-to-bilirubin ratio are poor predictors of survival for PAC,
whereas the MBSS is a far better predictor, confirming its clinical value. By adding the CA19-9-to-bilirubin
ratio to the MBSS the predictive characteristics improved.
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Introduction
Pancreatic adenocarcinoma (PAC) is the 13th most common
cancer worldwide and the 8th commonest cause of cancer mor-
tality.1 Upon presentation, 80% of patients have locally advanced
or metastatic disease and are not immediate surgical candidates.2
Predicting survival in patients who have resectable and unresect-
able PAC is a crucial step in optimizing personalized patient
management.3,4
Few clinical tools predict PAC survival and most of these are
designed for resectable disease. The Karnofsky performance scale,
while easy to use, is not specific to PAC.5 The Memorial Sloan-
Kettering nomogram is specific to PAC but remains fastidious,
only applies to resected patients and relies on histopathological
findings.6–8 The Glasgow prognostic score, which assesses the sys-
temic inflammatory response (C-reactive protein and albumin),
was shown to predict survival in unresectable9,10 and resectable11,12
PAC. However, any concomitant infectious process might yield
falsely elevated scores. The McGill surgical department has
published and validated a new symptom-based score that accu-
rately identifies PAC patients at baseline who will have increased
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survival, in both resected and unresected groups.4,13 The McGill
Brisbane Scoring System (MBSS) is assessed at the time of first
encounter and is based on smoking status, pain, jaundice and a
reported weight loss of more than 10% (Table 1). Although this
score was strongly associated with survival in multiple cohorts,
being even more accurate than radiology in non-resected patients,
its predictive characteristics have not been formally compared
with those of other strategies.
The carbohydrate antigen 19-9 (CA 19-9) was first discovered
by Koporowski et al.14 in a colorectal cancer cell line in 1979. Since
then, serum CA 19-9 elevations were linked to 27 different disease
processes, the most common being gastrointestinal malignancies,
hepato-biliary and pancreatic cancers.15 CA 19-9 is expressed on
the surface of cancer cells as a glycolipid and as a glycoprotein.
Carcinogenesis leads to an abnormal synthesis and accumulation
of this byproduct.15 CA 19-9 when expressed on the tumour cell
surface, may play a role in the invasion and metastasis process as
it is involved in cell adhesion pathways.16
CA 19-9 has become a well-established diagnostic tumour
marker for PAC.17 Increasing evidence points to its potential
as a peri-operative prognostic marker for survival from PAC.18
However, adenocarcinoma of the pancreatic head often presents
with biliary obstruction. In this context, a CA 19-9 elevation can
in fact be as a result of biliary obstruction, the cancer itself or a
combination of both.19 Hence a standardized method correcting
for obstruction-related CA 19-9 elevations is necessary to decrease
confounding. One method described in the literature is the CA
19-9-to-bilirubin ratio;20 however, this method remains to be vali-
dated or compared with alternate strategies.
The aim of this study was to assess and compare the test char-
acteristics of four strategies to predict survival in patients with
head PAC upon presentation: the MBSS, the CA 19-9, the CA
19-9/bilirubin ratio and the combined score of MBSS and CA
19-9/bilirubin ratio.
Methods
A retrospective review of the McGill University Health Center
(MUHC) tumour registrywas performed.Between 2005 and 2010,
data on 133 patients diagnosed with pancreatic adenocarcinoma
(PAC) of the head, as confirmed by histopathology, were available.
Thesepatients underwent either resectional or palliative treatment.
The diagnosis of PAC in patients with unresectable disease was
confirmed through biopsies taken at the time of the exploratory
laparotomy or during endoscopic ultra-sound. Patient demo-
graphics and clinical symptoms and characteristics at presentation
were recorded from charts and routine nutritional assessments.
The serum CA 19-9 and bilirubin levels prior to any intervention
were collected. At the MUHC, CA 19-9 is measured using the
Uni-Cell®DXI-800 Beckman Couter immunoassay (Beckman
Coulter, Inc., Brea, CA,USA). Note that there was very poor access
to CA 19-9 prior to 2007 in the province of Quebec, thus simulta-
neous measurements were available in only 52 patients (40%) that
were included in the final analysis. The Quebec Civil Registry was
used at the time of censoring to determine the date of death. If
patients were not reported as deceased, they were censored on 14
February 2011, allowing a minimum of 14-month follow-up for
the last patients included in this study.Theprimary outcomeof this
study was mortality at 9 months, a clinically significant endpoint
based on previous studies.4 Overall survival was also assessed.
Statistical analysis
Receiver-operating characteristic (ROC) curves were used to
determine an optimal cutoff for CA 19-9 and the CA 19-9-to-
bilirubin ratio for mortality at 9 months. The distribution of
baseline characteristics in each of the four strategies was com-
pared. These include demographics, resectable disease, resection
margins, whether patients had metastatic or locally advanced
disease and whether chemotherapy was administrated. The pre-
dictive characteristics for each of the four strategies were also
determined: sensitivity (Sen), specificity (Spec), positive predic-
tive value (PPV), negative predictive value (NPV), positive and
negative likelihood ratios (LR + and LR–, respectively) and ROC.
Particular attention was paid to the LR + , the LR– and the NPV as
these characteristics have more of a direct clinical impact.21
LR enlighten the clinician as to the accuracy with which a test
improves our diagnostic impression.21 The positive LR (LR+) is
calculated using the formula sensitivity/(1-specificity) whereas the
negative LR (LR-) is calculated using the formula (1-sensitivity)/
specificity.21 The initial impression is represented by the pre-test
probability and the usefulness of the test leads to a post-test prob-
ability. For a diagnostic test, a LR of 1 means that the post-test
probability is identical to the pretest probability, i.e. the test does
not improve our original diagnostic acumen. The usefulness of a
test is thus corroborated by how the LR affects the post-test prob-
ability: as LRs increase above 1, the post-test probability progres-
sively increases in relation to the pretest probability; as LRs
decrease below 1, the post-test probability decreases. In the case of
MBSS, the LR + informs the clinician on how the probability of
mortality at 9 months shifts when the MBSS is high, whereas the
LR– informs the clinician on how the probability of mortality at 9
months changes when the MBSS is low. An ideal test will have a
Table 1 McGill-Brisbane Symptom Score (adapted from Jamal
et al.4)
Symptom Points
Weight loss > 10% 8
Paina 5
Jaundiceb 4
Smokingc 4
Low score 0–9
High score 12–21
aPain: any pain, whether abdominal or back pain.
bJaundice: subjectively observed by the patient or healthcare worker.
cSmoking: over the past 5 years.
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very high LR + and very low LR–. An LR is considered significant
when the 95% confidence interval (CI) does not cross 1. Moreo-
ver, a high NPV indicates that a high proportion of patients with
a low MBSS survive beyond 9 months. For the NPV to be signifi-
cant, the test must perform better than chance, thus the 95% CI of
the NPV must not cross 50%.
Kaplan–Meier survival curves were used to visually evaluate the
predictive ability of each strategy. Wilcoxon’s test was used to
detect statistical significant (P < 0.050) differences between high
and low tests results for each strategy and a univariate COX analy-
sis was used to assess their association with survival.
In order to assess for selection bias, baseline characteristics of
the patients included in the study were compared with those of the
excluded patients, through chi-square, Fisher’s exact test and
anova when appropriate. Statistical analysis was performed using
STATA 13® (Statacorp, College Station, TX, USA).
Results
Patient characteristics are presented in Table 2. The 24 patients
(48%) who did not undergo a resection underwent palliative
intervention (endoscopic, surgical or both).
For CA 19-9, the optimal cutoff value was 100 U/ml with a
sensitivity of 80.0% and a specificity of 34.8% for mortality at 9
months (ROC area 0.584). For the CA 19-9/bilirubin ratio, the
optimal cutoff value was a ratio of 4.36 exhibiting a sensitivity and
specificity of 60.0% and 60.9%, respectively (ROC area 0.548).
The combined MBSS and CA 19-9/bilirubin ratio was defined as
‘high’ when the MBSS was high and the CA 19-9/bilirubin ratio
was greater than the cut offs. The distribution of baseline charac-
teristics was comparable among the groups for each of the four
strategies used (Table 3).
The predictive characteristics for all four strategies are pre-
sented in Table 4. The MBSS alone had the best NPV at 90.2%,
making it the most successful predictor of survival at 9 months.
The combined MBSS and CA 19-9/bilirubin ratio also had a sig-
nificant NPV of 76.7%. This combined score also showed the
highest PPV at 58.3%; however, it remained not significant.
The combined score (MBSS with CA 19-9/bilirubin ratio)
emerged as the most informative predictive strategy with the
highest LR + (2.20, 95% CI 1.21–4.01), followed by MBSS alone.
The MBSS alone also had the best LR– (0.25, 95% CI 0.10–0.63),
followed by the combined score (MBSS with CA 19-9/bilirubin
ratio). CA 19-9 alone had the worst predictive characteristics.
When correcting for the CA 19-9 for bilirubin at baseline, both LR
+ and LR– improved, but remained non-significant.
The Kaplan–Meier survival analyses illustrate the predictive
ability for each strategy (Figs 1–4). CA 19-9 alone was not able to
discriminate between survivors and non-survivors (P = 0.423;
Fig. 2). Correcting for bilirubin improved the predictive ability of
CA 19-9 and patients with a high CA 19-9/bilirubin ratio exhibited
a greater survival (Fig. 3). But again the combined MBSS and CA
19-9/bilirubin ratio was the most accurate strategy in predicting
overall survival (P = 0.000; Fig. 4). The results of the univariate
survival analysis (Table 5) also found that only CA 19-9 and com-
binedMBSS and the CA 19-9/bilirubin ratio were significant inde-
pendent predictors of survival, whereas CA 19-9 alone was not.
The bias analysis comparing baseline characteristics in the
selected patients and those excluded for the lack of CA 19-9 found
no significant differences (Table 6).
Discussion
The present study shows that the combination ofMBSS and theCA
19-9/bilirubin ratiohas the greatest ability of any strategy topredict
mortality at 9 months and overall survival from head PAC.
Although CA 19-9 has been increasingly used in the diagnosis and
prognosis of pancreatic cancer, it has many inherent limitations.
CA 19-9 has a limited use as a universally applicable biomarker as
it is related to the sialylated Lewis blood group antigens, absent in
5–10% of the population making it inapplicable in these patients
whose status is not routinely known upon initial clinical presenta-
tion.15,17,22 Moreover, a particular mechanism of CA 19-9 elevation
is reduced excretion secondary to biliary obstruction which is
nearly ubiquitous in patients with head PAC;19,23,24 this process can
lead to confounding in the interpretation of the elevated value. In
spite of these significant and often overlooked limitations, there is
an increasing interest in the use of CA 19-9 to predict survival in
Table 2 Patient characteristics
Total (n = 52) Number of patients (%)
Median age (years) 67.5 (60.5–76.0)
Male 28 (53%)
Underwent resection 28 (53%)
R0 21 (40.4%)
R1 7 (13.5%)
Metastatic disease 13 (25%)
Locally advanced 9 (17.3%)
Chemotherapy 38 (73.1%)
Size of the tumour (cm) 3.35 (2.6–4.0)
High MBSS 32 (62%)
MBSS symptoms
Weight loss >10% 32 (62%)
Pain 31 (60%)
Jaundice 41 (79%)
Smoking 11 (21%)
Bilirubin (mmol/l) 45.7 (15.0–181.8)
CA 19-9 (U/ml) 365.9 (107–1111.5)
CA 19-9/bilirubin ratio 4.67 (1.63–39.8)
Median overall survival (months) 11.0 (5.5–22.0)
Resected patients 16.5 (11.0–31.5)
Unresectable patients 11.0 (5.5–22)
MBSS, McGill Brisbane Scoring System; CA 19-9, carbohydrate antigen
19-9.
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both resectable15,18,25–28 and unresectable patients with PAC.5,22,29,30
In the present cohort, CA 19-9 alone did not perform as well in
predicting survival, and exhibited the least useful test characteris-
tics, which highlights the need for a more accurate predictive
strategy.This phenomenon canbe explainedby the fact that 76%of
patients presented with jaundice, a significant confounder of high
CA 19-9 values. Several methods have been used in an attempt to
adjust for hyperbilirubinaemia.A study byMann et al. analysed the
change in CA 19-9 levels after biliary decompression.19 Although
conceptually appealing, the use of such a drop in bilirubin (slope)
might be clinically limited. The most prevalent method used to
adjust CA 19-9 involves dividing the pre-operative levels by the
total bilirubin serum level when the latter is elevated.20,31 Unfortu-
nately, none of these studies have validated or compared their
results with CA 19-9 alone or to other strategies. The current study
is the first to validate the use of CA 19-9 to the bilirubin ratio by
demonstrating that its predictive abilities are superior to that of CA
19-9 alone in adenocarcinomas of the head of the pancreas.
This study also confirms the superior usefulness of the MBSS,
in both resectable and non-resectable patients.4 The MBSS is a
bedside, user-friendly score that predicts survival better than pre-
operative radiological findings or resection margin status.13 These
results demonstrate a significant clinical advantage in using the
combined MBSS and the CA 19-9/bilirubin ratio. Indeed the LR +
is higher for the combined score when compared with MBSS
alone or the CA 19-9/bilirubin ratio alone enabling the clinician to
predict who is at greater risk of dying. This could improve the
stratification of patients into therapeutic trials by removing the
heterogeneity of survival associated with the diagnosis of head
PAC. The combinedMBSS and CA 19-9/bilirubin ratio thus opens
Table 3 Distribution of patient characteristics by strategy use
Median age
(years)
Male Underwent
resection
R1 Metastatic
PAC
Locally
advanced
PAC
Chemotherapy Median overall
survival (months)
High MBSS (n = 32) 69.5 (60.5–76.0) 18 (56.2%) 16 (50.0%) 6 (18.8%) 10 (31.3%) 4 (12.5%) 21 (65.6%) 8.0 (3.5–12.5)
Low MBSS (n = 20) 66.0 (60.5–75.0) 10 (50.0%) 12 (60.0%) 1 (5.0%) 3 (15.0%) 5 (25.0%) 17 (85.0%) 17.5 (11.5–35.0)
P-value 0.314 0.660 0.358 0.184 0.324 0.280 0.200 0.002*
High CA 19-9 (n = 40) 69.0 (60.5–77.0) 21 (52.5%) 19 (47.5%) 6 (15.0%) 11 (27.5%) 8 (20.0%) 28 (70.0%) 10.5 (4.5–18.5)
Low CA 19-9 (n = 12) 65.5 (60.5–69.5) 7 (58.3%) 9 (75.0%) 1 (8.3%) 2 (16.7%) 1 (8.3%) 10 (83.3%) 17.0 (8.5–33.5)
P-value 0.126 0.722 0.113 0.371 0.706 0.666 0.475 0.117
High CA 19-9/bilirubin
ratio (n = 29)
68.0 (60.0–77.0) 15 (51.7%) 12 (41.4%) 4 (13.0%) 10 (34.5%) 5 (17.2%) 19 (65.5%) 8.0 (3.0–12.0)
Low CA 19-9/bilirubin
ratio (n = 23)
67.0 (61.0–74.0) 13 (56.5%) 16 (69.5%) 3 (13.7%) 3 (13.0%) 4 (17.4%) 19 (82.6%) 17.0 (9.0–32.0)
P-value 0.462 0.730 0.0643* 0.980 0.111 1.000 0.217 0.026*
High combined MBSS
and CA19-9/Bilirubin
Ratio (n = 23)
66.0 (57.0–70.0) 13 (56.5%) 12 (41.4%) 4 (17.3%) 8 (34.7%) 2 (8.7%) 14 (60.9%) 8.0 (2.0–11.0)
Low combined MBSS
and CA19-9/Bilirubin
Ratio (n = 29)
68.0 (62.0–75.0) 15 (51.7%) 12 (52.2%) 3 (10.3%) 5 (17.2%) 7 (24.1%) 24 (82.8%) 17.0 (11.0–32.0)
P-value 0.961 0.730 0.483 0.381 0.147 0.268 0.116 0.001*
Table 4 Predictive characteristics of the four strategies
Value (95% CI) MBSS CA 19-9 CA 19-9/Bilirubin Ratio MBSS and Ca19-9/
Bilirubin Ratio
PPV 45.6% (32.4–59.3%) 40.5% (25.6–56.7%) 50.0% (31.3–68.7%) 58.3% (36.6–77.9%)
NPV 90.2% (76.9–97.3%)* 69.2% (38.6–90.9%) 75.0% (53.3–90.2%)* 76.7% (57.7–90.1%)*
LR + 1.90 (1.42-2.55)* 1.10 (0.82-1.47) 1.57 (0.99-2.49) 2.20 (1.21-4.01)*
LR - 0.25 (0.10-0.63)* 0.72 (0.25-2.05) 0.52 (0.25-1.10) 0.48 (0.25-0.91)*
Sensitivity 86.7% (69.3–96.2%)* 81% (58.1–94.6%)* 71.4% (47.8–88.7%) 66.7% (43.0–85.4%)
Specificity 54.4% (41.9–64.4%) 54.4% (41.9–64.4%) 54.5% (36.4–71.9%) 69.7% (51.3–84.4%)*
ROC area 0.71 (0.62-0.79)* 0.54 (0.42-0.65) 0.62 (0.49-0.75) 0.68 (0.55-0.81)*
*statistically significant. MBSS, McGill Brisbane Scoring System; CA 19-9, carbohydrate antigen 19-9.
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the door to a more personalized treatment approach, perhaps akin
to ‘clinical’ microarray.
The limitations of this study are those inherent to retrospec-
tive chart reviews. There is a potential for misclassification bias
with respect to some of the MBSS criteria. Using a prospectively
collected database may have reduced some of these biases.
Another potential bias is the exclusion of patients who did not
have simultaneous CA 19-9 and bilirubin levels available at pres-
entation. However, when comparing the baseline characteristics
for the included compared with all patients there were no sta-
tistically significant differences suggesting that no significant
selection bias was introduced through this exclusion criteria.
One potential confounder could be the simultaneous study of
both palliative and resected patients. Both resectable and unre-
sectable patients were considered together in this analysis as pre-
vious work demonstrated that the hazard ratio for the MBSS was
strikingly similar in both groups. This suggests that the MBSS
performs just as well among resectable and unresectable
patients. In order to determine the NPV, the prevalence of ‘death
at 9 months’ was thus chosen as a convenient measure, and has
also been previously reported on.4 A thorough analysis of the
distribution of the MBSS, the CA 19-9 and the CA 19-9-
bilirubin ratio according to resection status failed to reveal major
differences.
Figure 1 Kaplan–Meier survival estimates for high and low McGill Brisbane Scoring System (MBSS)
Figure 2 Kaplan–Meier estimates for high and low carbohydrate antigen 19-9 (CA 19-9)
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The combined score is thus useful in predicting outcomes, irre-
spective of resectability status. In fact, the advantage of using a
mixed cohort of resectable and unresectable PAC patients under-
scores its applicability to actual clinical practice.2
Conclusion
The study presented here study shows that the combination of
MBSS and the CA 19-9/bilirubin ratio has very strong predictive
Figure 3 Kaplan–Meier survival estimates for a high and low carbohydrate antigen 19-9 (CA 19-9)/bilirubin ratio
Figure 4 Kaplan–Meier survival estimates for a high and low combined score
Table 5 Univariate Cox analysis (results presented in hazard ratios with 95% confidence intervals)
MBSS CA 19-9 CA 19-9/bilirubin ratio MBSS and Ca19-9/
bilirubin ratio
HR 2.96 (1.19–7.32) 1.52 (0.55–4.14) 2.34 (0.99–5.55) 4.55 (1.91–10.82)
P-value 0.019* 0.409 0.052 0.001*
MBSS, McGill Brisbane Scoring System; CA 19-9, carbohydrate antigen 19-9; HR, hazard ratio.
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characteristics for mortality in head PAC patients and is the most
clinically meaningful predictor of survival. These results empha-
size the importance of clinical symptoms in determining patient
prognosis, and support the evaluation of PAC patients by meas-
uring the CA 19-9 and bilirubin levels.
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